Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 2Squamous Intraepithelial Lesions 2Precancerous Conditions 2Warts 1Sarcoma, Kaposi 1Sarcoma 1Papillomavirus Infections 1Papilloma 1High-grade Anal Intraepithelial Neoplasia 1HIV Infections 1HIV 1Condylomata Acuminata 1Anus Neoplasms 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1AIDS-Related Opportunistic Infections 1AIDS-Related Complex 1

Interventions

Cryotherapy 11resiquimod 6Cantharidin 5PRA1 protein, Candida albicans 4Tuberculin 3Salicylic Acid 3Cholecalciferol 3plerixafor 2VP-102 2Solutions 2Sodium Chloride 2Saline Solution 2Photochemotherapy 2Percutaneous Collagen Induction 2N-phenylacetoaminomethylene-DL-p-nitrophenylalanine 2Measles-Mumps-Rubella Vaccine 2Lasers 2Hydrogen Peroxide 2Human Papillomavirus Recombinant Vaccine nonavalent 23-ingenyl angelate 22-Propanol 2methyl 5-aminolevulinate 1lactic acid, salicylic acid drug combination 1human papillomavirus vaccine, L1 type 16, 18 1green tea extract polyphenone E 1gluconic acid 1ethyl pyruvate 1compound W 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1Zinc Sulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Warts × Cidofovir × Clear all
NCT02567149 2017-07-02

Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

University of Minnesota

Phase 2 Withdrawn

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡